UPDATE: DexCom (DXCM) Falls, Insulet (PODD) Gains Mid-Day Amid Rumors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
DexCom (DXCM) Reportedly in Talks to Acquire Insulet (PODD), Analyst Cautious
May 24, 2022 7:47 AM EDTDexCom (NASDAQ: DXCM) is in talks to buy out diabetes device maker Insulet Corp (NASDAQ: PODD), according to Bloomberg.
The two companies are currently negotiating the deal and an agreement could be reached over the following weeks. However, there are no guarantees that the deal will be closed, the report said.
As of Mondays close, Insulet and Dexcom had market valuations of $14.1 billion and $31.8 billion, respectively.
The negotiations between Dexcom and Insulet... More
Roivant Sciences' (ROIV) Dermavant Announces FDA Approval of VTAMA Cream
May 24, 2022 6:01 AM EDTDermavant Sciences (a subsidiary of Roivant Sciences (NASDAQ: ROIV)) today announced that the U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class.
We are delighted with our FDA-approved label for VTAMA cream, which is for adults with psoriasis, regardless of disease severity, and with an unlimited duration of use. In anticipation of todays approval, we... More
DexCom (DXCM) is in talks to acquire Insulet (PODD) - Bloomberg
May 23, 2022 6:12 PM EDTDexCom (NASDAQ: DXCM) is in talks to acquire Insulet (NASDAQ: PODD), according to Bloomberg, citing people with knowledge of the matter.
... More
